| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $31,920,659 ) |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI176366 | Modulation of pathogenic T cells in EAE | 000 | 2 | NIH | 10/31/2024 | $210,126 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI185642 | T cell-mediated control of dermal fibroblast gene programs and dysfunction in scleroderma | 000 | 2 | NIH | 4/25/2025 | $216,625 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01DK132593 | Harnessing engineered T regulatory cells to promote beta cell health in T1D | 000 | 4 | NIH | 2/28/2025 | $975,699 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI183670 | T Cell Epigenomic Drivers of Disease Flares in Multiple Sclerosis | 000 | 2 | NIH | 4/16/2025 | $216,625 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI169893 | Reprogramming of tissue structural cells by cutaneous CD4+ T cells | 000 | 3 | NIH | 4/18/2025 | $627,326 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | UM1AI109565 | Immune Tolerance Network | 002 | 12 | NIH | 3/28/2025 | $0 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | UM1AI109565 | Immune Tolerance Network | 002 | 12 | NIH | 3/28/2025 | $0 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R03AI190880 | Building tools to study commensal-specific CD8+ T cells in the small intestine | 000 | 1 | NIH | 3/28/2025 | $86,650 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI188483 | Characterizing circulating and visceral T cells specific for the autoantigen integrin αvβ6 in ulcerative colitis | 000 | 1 | NIH | 12/4/2024 | $252,152 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | UM1AI109565 | Immune Tolerance Network | 001 | 12 | NIH | 1/31/2025 | $26,297,760 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | UM1AI109565 | Immune Tolerance Network | 001 | 12 | NIH | 1/31/2025 | $1,000,013 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI158624 | Commensal-specific T cell function in skin wound repair | 000 | 5 | NIH | 1/22/2025 | $569,699 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI188364 | Foxp3 isoform expression and regulation of autoantibody production | 000 | 1 | NIH | 11/19/2024 | $709,019 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI176365 | DCs as clinical targets of anti-integrin therapy in IBD | 001 | 2 | NIH | 11/22/2024 | $210,126 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI185925 | Plasmacytoid dendritic cells and IgA autoantibodies in SLE | 000 | 2 | NIH | 4/24/2025 | $853,754 |
| | 2025 | 2025 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI181275 | Regulatory T cells maintain immune homeostasis through translation control | 000 | 2 | NIH | 10/24/2024 | $831,400 |
| | 2025 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI176365 | DCs as clinical targets of anti-integrin therapy in IBD | 000 | 1 | NIH | 10/31/2024 | $0 |
| | 2025 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | F32HL172506 | Requirement of HIF2a signaling in Th2 cell differentiation and allergic asthma | 000 | 1 | NIH | 10/31/2024 | $0 |
| | 2025 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01DK140792 | Clonal expansion: a marker of disease activity in stage 1 T1D | 000 | 1 | NIH | 2/19/2025 | $0 |
| | 2025 | 2023 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R56AI168995 | LITAF regulation of cell death and inflammatory responses | 000 | 1 | NIH | 2/14/2025 | $0 |
| | 2025 | 2021 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R03DK127475 | Using B cell features to explain heterogeneity in the rate of T1D progression | 000 | 2 | NIH | 12/26/2024 | $0 |
| | 2025 | 2021 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | UM1AI109565 | Immune Tolerance Network | 000 | 8 | NIH | 11/13/2024 | -$1,136,315 |
|
| Issue Date FY: 2024 ( Subtotal = $55,112,361 ) (Continued on the next page) |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI169893 | Reprogramming of tissue structural cells by cutaneous CD4+ T cells | 000 | 2 | NIH | 6/11/2024 | $627,326 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI166835 | Dissecting T and B cell dysregulation in people with Down syndrome | 000 | 3 | NIH | 7/19/2024 | $677,851 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI166835 | Dissecting T and B cell dysregulation in people with Down syndrome | 001 | 3 | NIH | 8/23/2024 | $453,873 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01DK132593 | Harnessing engineered T regulatory cells to promote beta cell health in T1D | 000 | 3 | NIH | 2/21/2024 | $975,699 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI181275 | Regulatory T cells maintain immune homeostasis through translation control | 002 | 1 | NIH | 9/3/2024 | $87,014 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI181275 | Regulatory T cells maintain immune homeostasis through translation control | 000 | 1 | NIH | 12/13/2023 | $801,433 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI181275 | Regulatory T cells maintain immune homeostasis through translation control | 001 | 1 | NIH | 12/15/2023 | $0 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI158624 | Commensal-specific T cell function in skin wound repair | 001 | 4 | NIH | 5/24/2024 | $58,732 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI158624 | Commensal-specific T cell function in skin wound repair | 000 | 4 | NIH | 12/29/2023 | $528,587 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI185925 | Plasmacytoid dendritic cells and IgA autoantibodies in SLE | 001 | 1 | NIH | 9/3/2024 | $85,418 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01AI185925 | Plasmacytoid dendritic cells and IgA autoantibodies in SLE | 000 | 1 | NIH | 6/12/2024 | $768,769 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01DK140792 | Clonal expansion: a marker of disease activity in stage 1 T1D | 000 | 1 | NIH | 7/8/2024 | $1,273,578 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | F32HL172506 | Requirement of HIF2a signaling in Th2 cell differentiation and allergic asthma | 001 | 1 | NIH | 1/10/2024 | -$71,792 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | F32HL172506 | Requirement of HIF2a signaling in Th2 cell differentiation and allergic asthma | 000 | 1 | NIH | 12/29/2023 | $71,792 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI185642 | T cell-mediated control of dermal fibroblast gene programs and dysfunction in scleroderma | 001 | 1 | NIH | 9/11/2024 | $25,995 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI185642 | T cell-mediated control of dermal fibroblast gene programs and dysfunction in scleroderma | 000 | 1 | NIH | 6/12/2024 | $233,955 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI183670 | T Cell Epigenomic Drivers of Disease Flares in Multiple Sclerosis | 001 | 1 | NIH | 9/11/2024 | $25,995 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI183670 | T Cell Epigenomic Drivers of Disease Flares in Multiple Sclerosis | 000 | 1 | NIH | 5/30/2024 | $233,955 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI172140 | Mechanisms of Il-2-mediated immune tolerance | 000 | 2 | NIH | 7/16/2024 | $216,625 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI176366 | Modulation of pathogenic T cells in EAE | 001 | 1 | NIH | 9/11/2024 | $25,995 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI176366 | Modulation of pathogenic T cells in EAE | 000 | 1 | NIH | 11/13/2023 | $233,955 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI171921 | Regulation of TLR signaling in anti-commensal B cell responses and mucosal inflammation | 000 | 2 | NIH | 3/21/2024 | $216,625 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R21AI178562 | Identifying autoimmune associated genes in patrolling monocytes that promote lupus nephritis | 000 | 2 | NIH | 5/30/2024 | $216,625 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | R01HL149676 | Immune Checkpoints in Acute Respiratory Distress Syndrome (IC-ARDS) | 000 | 5 | NIH | 7/18/2024 | $418,197 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | U19AI167891 | Systems Immunology profiling of respiratory viral infections in vulnerable populations | 003 | 3 | NIH | 8/21/2024 | $0 |
| | 2024 | 2024 | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON | 1201 9TH AVE | SEATTLE | WA | 98101-2795 | KING | USA | U19AI167891 | Systems Immunology profiling of respiratory viral infections in vulnerable populations | 002 | 3 | NIH | 4/23/2024 | $228,383 |
|
